Oppenheimer & Co. Inc. Purchases New Holdings in Exelixis, Inc. (NASDAQ:EXEL)

Oppenheimer & Co. Inc. purchased a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 16,836 shares of the biotechnology company's stock, valued at approximately $561,000.

A number of other hedge funds also recently bought and sold shares of EXEL. Seizert Capital Partners LLC boosted its stake in Exelixis by 8.0% during the 3rd quarter. Seizert Capital Partners LLC now owns 469,940 shares of the biotechnology company's stock valued at $12,195,000 after purchasing an additional 34,875 shares during the last quarter. Los Angeles Capital Management LLC increased its holdings in Exelixis by 124.0% in the 3rd quarter. Los Angeles Capital Management LLC now owns 1,790,855 shares of the biotechnology company's stock worth $46,473,000 after buying an additional 991,494 shares in the last quarter. Tri Ri Asset Management Corp purchased a new position in Exelixis in the 3rd quarter worth about $4,396,000. CWA Asset Management Group LLC bought a new position in Exelixis during the 3rd quarter valued at about $577,000. Finally, Blue Trust Inc. boosted its holdings in shares of Exelixis by 134.7% during the 4th quarter. Blue Trust Inc. now owns 14,302 shares of the biotechnology company's stock valued at $476,000 after acquiring an additional 8,208 shares during the last quarter. Institutional investors own 85.27% of the company's stock.

Exelixis Stock Up 1.5 %

NASDAQ EXEL traded up $0.58 on Monday, reaching $39.16. The company had a trading volume of 3,877,616 shares, compared to its average volume of 2,080,962. The firm's 50 day moving average price is $34.99 and its 200 day moving average price is $32.12. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $40.00. The stock has a market capitalization of $10.96 billion, a PE ratio of 22.12, a price-to-earnings-growth ratio of 1.13 and a beta of 0.57.

Remove Ads

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts' consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts expect that Exelixis, Inc. will post 2.04 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on EXEL shares. JMP Securities reissued a "market outperform" rating and set a $41.00 price objective on shares of Exelixis in a report on Thursday, January 23rd. Morgan Stanley raised Exelixis from an "equal weight" rating to an "overweight" rating and increased their price target for the company from $30.00 to $40.00 in a report on Monday, January 27th. Oppenheimer downgraded Exelixis from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $41.00 to $33.00 in a research note on Friday, January 24th. Barclays upped their price objective on Exelixis from $25.00 to $29.00 and gave the company an "equal weight" rating in a research report on Thursday, February 13th. Finally, BMO Capital Markets cut Exelixis from an "outperform" rating to a "market perform" rating and raised their target price for the stock from $36.00 to $40.00 in a research report on Friday, December 20th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average price target of $37.24.

Insider Buying and Selling

In related news, Director Bob Oliver sold 18,647 shares of Exelixis stock in a transaction dated Tuesday, February 25th. The stock was sold at an average price of $37.25, for a total value of $694,600.75. Following the completion of the transaction, the director now owns 33,514 shares in the company, valued at approximately $1,248,396.50. This trade represents a 35.75 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Christopher J. Senner sold 29,314 shares of the business's stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $36.14, for a total value of $1,059,407.96. Following the sale, the chief financial officer now directly owns 779,607 shares in the company, valued at $28,174,996.98. The trade was a 3.62 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 140,343 shares of company stock worth $5,177,234. Insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.